You are here

  • Home
  • Archive
  • Volume 10, Issue 1
  • Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment

Citation Tools

Article menu
Commentary
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Gambale E, Fancelli S, Caliman E, et al
Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment
Journal for ImmunoTherapy of Cancer 2022;10:e003540. doi: 10.1136/jitc-2021-003540